Skip to main content
    T

    Tevogen Bio Holdings Inc. (TVGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.22
    +0.22 (+3.67%)

    Market Cap: $406.59M

    Last updated: Nov 17, 2026 at 3:04 AM ET

    Tevogen Bio Holdings Inc. (TVGN) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Tevogen Bio Holdings reported revenue of $0 for the fiscal year ended Jun 30, 2026. That year, net income was -$26.28M, operating cash flow was -$12.33M and free cash flow was -$12.39M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$5.76M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of $26.14M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$0N/AN/AN/AN/A
    Jun 2025$0N/AN/AN/AN/A
    Jun 2024$0N/AN/AN/AN/A
    Jun 2023$0N/AN/AN/AN/A
    Jun 2022$0N/AN/AN/AN/A
    Annual, fiscal years ended Jun 2022 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
    Cost of revenueN/A$403.58K$378.36KN/AN/A
    Gross profitN/A-$403.58K-$378.36KN/AN/A
    Research and development$11.11M$31.03M$4.40M$5.77M$2.96M
    Operating income-$26.14M-$53.56M-$8.84M-$953.08K-$4.62M
    Net income-$26.28M-$10.11M-$60.48M$4.41M-$15.60M
    EBITDA-$25.57M-$13.14MN/A$4.64MN/A
    Fiscal years ended Jun 2022 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$396.59K$0$0$0$0$0$0
    Gross profit-$60.14K-$59.05K-$85.79K-$27.23K-$290.78K-$103.55KN/A-$101.74K-$99.99K-$98.30K-$100.87K-$93.58K
    Operating income-$5.66M-$5.40M-$4.61M-$5.73M-$5.44M-$10.36M-$9.42M-$6.09M-$8.60M-$29.52M-$2.01M-$2.33M
    Net income-$5.76M-$5.45M-$4.68M-$5.73M-$5.50M-$10.37M-$9.44M-$5.91M-$6.05M$11.26M-$3.63M-$3.90M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, total debt of $6.38M exceeded cash and equivalents by $5.83M. Shareholder equity was negative, at -$8.23M, as total liabilities of $12.62M exceeded total assets of $4.38M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
    Total assets$4.38M$3.46M$5.51M$7.74M$7.66M
    Current assets$1.54M$2.36M$1.72M$5.84M$7.17M
    Cash and equivalents$552.37K$1.28M$1.05M$5.48M$7.12M
    Total liabilities$12.62M$10.14M$99.93M$41.69M$24.15M
    Short-term debt$1.98M$1.88M$80.96M$278.21KN/A
    Long-term debt$4.40M$1.00M$14.22M$39.30M$23.48M
    Shareholder equity-$8.23M-$6.67M-$94.43M-$33.95M-$16.49M
    Fiscal years ended Jun 2022 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$4.73M$4.92M$4.38M$4.49M$4.27M$4.07M$3.46M$4.29M$3.31M$3.36M$5.51M$6.36M
    Total liabilities$13.62M$14.76M$12.62M$12.32M$13.75M$11.79M$10.14M$10.48M$10.94M$9.17M$99.93M$97.16M
    Cash and equivalents$1.08M$692.30K$552.37K$1.04M$685.23K$1.97M$1.28M$2.33M$1.14M$1.32M$1.05M$2.61M
    Shareholder equity-$8.89M-$9.84M-$8.23M-$7.82M-$9.48M-$7.72M-$6.67M-$6.19M-$7.63M-$5.80M-$94.43M-$90.80M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
    Operating cash flow-$12.33M-$12.00M-$8.17M-$8.66M-$5.27M
    Capital expenditures$64.44K$0$133.00K$479.04K$109.73K
    Free cash flow-$12.39M-$12.00M-$8.30M-$9.13M-$5.38M
    Investing cash flow-$64.44KN/A-$133.00K-$479.04K-$109.73K
    Financing cash flow$11.66M$12.23M$3.87M$7.50M$12.50M
    Fiscal years ended Jun 2022 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$3.01M-$2.73M-$2.18M-$3.65M-$3.19M-$3.31M-$3.05M-$3.80M-$2.98M-$2.16M-$1.98M-$1.80M
    Capital expenditures$3$1$64.43K$4$3$3$0$1$0$5$2$2
    Free cash flow-$3.01M-$2.73M-$2.25M-$3.65M-$3.19M-$3.31M-$3.05M-$3.80M-$2.98M-$2.16M-$1.98M-$1.80M
    Last 12 quarters

    Frequently Asked Questions About TVGN

    What is Tevogen Bio Holdings' annual revenue?

    Tevogen Bio Holdings reported revenue of $0 for the fiscal year ended Jun 30, 2026.

    Is Tevogen Bio Holdings profitable?

    No. Tevogen Bio Holdings reported net income of -$26.28M for the fiscal year ended Jun 30, 2026.

    How much free cash flow does TVGN generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of -$12.33M minus capital expenditures of $64.44K produced free cash flow of -$12.39M.

    How much debt does Tevogen Bio Holdings have?

    The balance sheet dated Jun 30, 2026 reported long-term debt of $4.40M, short-term debt of $1.98M and cash and equivalents of $552.37K.